🌟 Product Overview
Finerenone (CAS: 1050477-31-0) is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with the molecular formula C₂₁H₂₂N₄O₃ and molecular weight 378.42. It is clinically proven to slow chronic kidney disease (CKD) progression and reduce cardiovascular risks in patients with type 2 diabetes12. Approved under the brand name Kerendia®, it targets aldosterone-induced inflammation and fibrosis, making it vital in pharmaceutical formulations, diabetic nephropathy therapy, and cardiovascular research35.
✅ Key Advantages
💊 High Purity: ≥99% HPLC-certified, meeting USP/EP standards for pharmaceutical use24.
🔬 Stability: Stable for 24 months at -20°C (powder form) with rigorous batch consistency14.
📈 Clinical Impact: Reduces CKD progression risk by 18% and cardiovascular events by 14% in trials36.
🧪 Solubility: DMSO-soluble (76 mg/mL), ideal for preclinical and formulation studies17.
📌 Applications
🏥 Diabetic Nephropathy: Core component of Kerendia® for managing CKD in diabetic patients35.
❤️ Cardiovascular Protection: Mitigates heart failure and myocardial infarction risks36.
🔍 Research: Explored for anti-fibrotic mechanisms in preclinical models58.
🔍 Quality Certifications
🏅 Compliance: Adheres to USP/EP guidelines with impurities <0.3% and residual solvents within limits24.
📜 Batch Testing: COA includes HPLC (>98%), NMR, and mass spectrometry data25.
📈 Market Trends
The global CKD therapeutics market is projected to grow at 7.2% CAGR (2025–2030)36. Finerenone’s approval in 40+ countries and expanding clinical trials (e.g., heart failure studies) position it as a leader in non-steroidal MRAs36.
China
